

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION

COLLABORATION WITH NATIONAL RESEARCH COUNCIL OF CANADA TO ADVANCE CLINICAL TRIAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5) IN CANADA

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, the Company and National Research Council of Canada initiated the collaboration to advance clinical trial for the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (the “**Ad5-nCoV**”) in Canada. The clinical trial will start from phase I/II, aiming for accelerated Phase III clinical trial to demonstrate the efficacy of candidate vaccine Ad5-nCoV.

The ownership of the Ad5-nCoV and all intellectual property rights generated in the above-mentioned collaboration belong to the Company and the Institute of Biotechnology, Academy of Military Medical Sciences.

Given the vaccine efficacy need to be demonstrated in phase III clinical trials in countries where the pandemic outbreaks are occurring, the Company plans to carry out phase III clinical trials in more countries with high incidence rate and clinical study capabilities.

Ad5-nCoV is jointly developed by the Company and the Institute of Biotechnology, Academy of Military Medical Sciences. It is a genetic engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein, which intends to be used to prevent the disease caused by the novel coronavirus COVID-19.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The safety and efficacy of Ad5-nCoV are subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or market Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 13, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.